Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit

Rhea-AI Summary

Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2025, at 2:30 PM ET. Investors can access the live webcast through Whitehawk's IR website, with the recording remaining available for approximately 30 days after the event.

[]

News Market Reaction – WHWK

-3.27%

-3.27% Session move

In the trading session that priced this news, WHWK declined 3.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET. 

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About Whitehawk Therapeutics 

Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.

Contact:
IR@whitehawktx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summit-302461639.html

SOURCE Whitehawk Therapeutics, Inc.

FAQ

When is Whitehawk Therapeutics (WHWK) presenting at the TD Cowen Oncology Summit 2025?

Whitehawk Therapeutics' CEO will participate in a fireside chat on May 28, 2025, at 2:30 PM ET during the TD Cowen 6th Annual Oncology Innovation Summit.

Who will represent Whitehawk Therapeutics (WHWK) at the TD Cowen Oncology Summit?

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, will represent the company at the summit.

How can investors access Whitehawk Therapeutics' (WHWK) presentation at the TD Cowen Summit?

Investors can access the live webcast through Whitehawk Therapeutics' IR website, and a replay will be available for approximately 30 days following the event.

What is Whitehawk Therapeutics' (WHWK) main business focus?

Whitehawk Therapeutics is an oncology therapeutics company that applies advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments.